Table 1 Characteristics of patients at baseline and after etanercept/placebo treatment
From: Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial
Before etanercept (n = 10) | Before placebo (n = 10) | After etanercept (n = 10) | After placebo (n = 10) | |
|---|---|---|---|---|
Sex (female/male) | 6/4 | 7/3 | - | - |
Age (years) | 72.6 ± 2.6 | 71.4 ± 3.6 | - | - |
BMI (kg/m 2 ) | 23.6 ± 3.4 | 24.9 ± 4.1 | - | - |
Blood pressure (systolic/diastolic, mmHg) | 160 ± 5/87 ± 4 | 159 ± 4/87 ± 5 | - | - |
Smokers (n) | 2 | 3 | - | - |
Hypertension (n) | 6 | 3 | - | - |
Hypercholesterolemia (n) | 3 | 2 | - | - |
Physical activity level before PMR onset (1, high; 2, medium; 3, low) | 1.4 ± 0.1 | 1.9 ± 0.2 | - | - |
Physical activity level (1, high; 2, medium; 3, low) | 2.9 ± 0.1 | 2.9 ± 0.1 | 2.7 ± 0.2 | 3.0 ± 0 |
Morning stiffness (min) | 98 ± 16 | 117 ± 19 | 70 ± 17 | 103 ± 21 |
Patients' assessment of pain, VAS (0-10 cm) | 6.2 ± 0.7 | 5.0 ± 0.8 | 5.9 ± 0.6 | 5.4 ± 0.5 |
Cumulative intake of tramadol (tablets/14 days) | - | - | 47 ± 8 | 55 ± 12 |